NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

MannKind Corporation (MNKD) Stock Analysis

MannKind Corporation (MNKD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MNKD

$4.06

+$0.10 (+2.53%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MNKD with… →

MNKD Key Statistics

As of Sep 4, 2026
Trading
Open
$3.92
Previous Close
$3.96
Day's Range
3.92–4.10
52-Week Range
2.23–6.51
Volume
2.81M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.10
Valuation
Market Cap
$1.31B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
31.84
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
4.39
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.32
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.15
Financials (FY)
Revenue (FY)
$348.97M+22.23%
Net Income (FY)
$5.86M−78.75%
Profit marginThe share of revenue left as profit after all costs and taxes.
−11.08%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
321.54M
1-Year Return
−23.97%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
4.53M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MNKD Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−28.40%
2025−11.82%
2024+76.65%
2023−30.93%
2022+20.59%
2021+39.62%
2020+142.64%
2019+21.70%
2018−54.31%
2017−27.50%
2016 (partial year)−36.00%

As of September 4, 2026.

MNKD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$348.97M$5.86M1.7%
2024$285.50M$27.59M9.7%
2023$198.96M−$11.94M−6.0%
2022$99.77M−$87.40M−87.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$348.97M$261.01M$46.55M$5.86M1.7%
2024$285.50M$208.90M$68.68M$27.59M9.7%
2023$198.96M$136.19M$10.59M−$11.94M−6.0%
2022$99.77M$42.27M−$68.92M−$87.40M−87.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MNKD Valuation vs Biotechnology Median

Median of 656 stocks
MetricMNKDBiotechnology medianvs median
P/S ratio3.3215.260.2x the median
Profit margin−11.08%0.00%11.1 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

MannKind Corporation (MNKD) is capitalised at $1.31B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 591.

Over the past 52 weeks the price has ranged from $2.23 to $6.51. MNKD last closed at $4.06 on September 4, 2026. That is +$0.10 (+2.53%) against the previous close. The latest close sits 82.06% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $348.97M. Against the prior fiscal year total of $285.50M, that is a change of +22.23%. The same year closed with net income of $5.86M. That is −78.75% against the prior fiscal year. The reported profit margin is −11.08%. That is 11.1 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.15.

Across the 4 fiscal years on file, revenue moves from $99.77M in 2022 to $348.97M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 31.84. The PEG ratio, which sets the P/E against expected earnings growth, reads 4.39. The price-to-sales ratio is 3.32. On price-to-sales that is 0.2 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.1. Daily returns over the trailing 10 years annualize to a volatility of 83.2%. The trailing one-year price return is −23.97%. Measured over 10 years, that is +0.93% a year compounded.

Growth & Income

No dividend is on file for MNKD.

2026 is still running; the price is −28.40% year to date. The strongest complete calendar year on file is 2020 at +142.64%; the weakest is 2018 at −54.31%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

MannKind Corporation (MNKD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
MannKind Corporation MNKD $1.31B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. MannKind Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About MannKind Corporation

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. Its products also include Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; FUROSCIX, a furosemide injection to treat fluid buildup in patients with chronic heart failure or chronic kidney disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Visit website →